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Abstract
Background: Patients with chronic hepatitis B virus infection (CHB) usually mount a modest T cell response against
HBV epitopes. In order to determine immunogenic epitopes of HBV recognized by HBV-specific T cells, previous
studies focused on previously confirmed HBV epitopes and assessed the T cell response by the number of
HBV-specific T cells by IFN-γ ELISPOT.
Methods: We studied T cell functionality by combined in silico methods predicting HBV-specific epitopes and
experimental investigations on the recognition of these epitopes. 30 chronic CHB patients and 10 patients with
resolved HBV (RHB) were included in the study. We identified epitopes from the literature and by in silico analysis.
These were evaluated for immunogenicity by use of synthetic peptides representing the epitopes through
exposure to PBMCs from patients with CHB or RHB by IFN-γ ELISPOT. The number of IFN-γ producing cells (SFC),
mean spot size (MSS) and stimulation index (SI) were recorded.
Results: The frequency of HBV-specific T cells producing IFN-γ after stimulation with HBV epitopes was similar in
CHB and RHB patients. CHB patients had a higher MSS SI than RHB patients. Patients not carrying the HLA-A2
genotype had higher SFC SI and MSS SI. Patients with HLA-A11 had higher MSS SI compared to non- HLA-A11
allele patients. HBeAg-positive patients had a lower MSS SI, and none of the HBeAg positive patients had the
HLA-A11 genotype. We found 3 immunogenic epitopes not described previously.
Conclusion: IFN-γ ELISPOT-determined MSS is an efficient marker for T cell recognition of epitopes. This experimental
measure showed the in silico analysis for epitope prediction to be a valuable tool in future studies on HLA genotypes
and HBV epitopes. This way our study now points to previously unappreciated consequences of carrying the HLA-A11
allele in terms of stronger immunity to HBV.
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Background
Hepatitis B virus (HBV) is the cause of a spectrum of
acute diseases including fatal hepatocellular necrosis.
More than 350 million people have chronic HBV infec-
tion, which causes approximately one million deaths per
year from the associated morbidities, liver cirrhosis and
cancer [1]. Several lines of evidence suggest that HBV
infection induces suppression of the immune response
to the viral components as a result of both viral tropism
and antigen release.
In patients with chronic HBV infection HBV-specific
T cells egress into the liver but present only a modest
anti viral response [2, 3]. By contrast, patients with an
acute, self-limited HBV infection usually mount a vigor-
ous polyclonal CTL response targeting multiple HBV
epitopes [4] and with sufficient longevity to be
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detectable several years after infection [5, 6]. Here we
show that this is a conclusion not always cogent in the
case of patients with a resolved HBV more than two
years ago.
As part of the studies to understand the immune re-
sponse to HBV infection, an important part of the efforts
has been focused on identifying highly immunogenic CTL
epitopes. One approach involves in silico predictions on
the dissociation constant (KD) for the binding of antigen-
derived peptides to the Human Leukocyte Antigen (HLA)
molecules, typically accompanied by experimental testing
of CTL response to these peptides or experimentally
tested ability of HLA molecules to bind these peptides. A
number of studies reported that binding between
HLA molecules and antigenic peptides characterized
by KD <500 nM appears to enable CTL responses [7].
However, other studies suggest that the effects of antigenic
epitopes not always correlate with the affinity of the
epitope-containing peptide to HLA [8, 9]. Previous studies
evaluated the immune response to HBV infection by test-
ing previously confirmed HBV epitopes and assessed the
T cell response by determining the frequency of reactive T
cells, typically by IFN-γ enzyme-linked immunosorbent
spot (ELISPOT) analysis. From such studies it was sug-
gested that the frequencies of antigen-specific CTLs may
not be the major determinant of immune-mediated pro-
tection in chronic hepatitis B, nor should immunothera-
peutic approaches only aim at raising the frequency of
HBV-specific T cells. Indeed, T cell functionality, such as
ability to produce cytokines, may also be important
parameters [10]. However, the correlation between
HLA affinity for epitope-containing peptides and T
cell cytokine production as estimated by ELISPOT
has not been comprehensively studied in the context
of chronic HBV infection.
Objectives
Here, we combine in silico methods for predicting HBV-
specific CTL epitopes and compare with the T cell re-
sponse in vitro. By comparing cells from patients with
chronic HBV infection (CHB) and patients with resolved
HBV infection (RHB), we show that the calculations
were efficient in predicting immunogenic epitopes rec-
ognized by T cells from CHB patients. Indeed, T cell
functionality calculated from the amount of IFN-γ pro-




The study population consisted of patients with CHB,
i.e., positive HBsAg status for more than six months,
followed in Aarhus University Hospital, and former pa-
tients with RHB previously seen in Aarhus University
Hospital. The diagnosis of acute HBV was based on clin-
ical and biochemical evidence of acute liver injury
according to standard diagnostic criteria of acute HBV
infection, i.e. elevated liver enzymes, positive HBsAg and
IgM-antibodies against HBcAg [11] and reviewed in
[12]. Written consent was obtained from each partici-
pant, including consent to publish all personal infor-
mation contained in Table 3. The study was approved
by the The Central Denmark Region Committees on
Health Research Ethics, ref. number M-40-12 and the
National Data Protection Agency journal number
2012-41-0028.
Virological analyses
HBsAg, HBeAg, anti-HBe, anti-HBc, anti-HBs, HIV Ag/
Ab, and anti-HCV were determined by commercially
available chemiluminescense assays on the Architect sys-
tem (Architect, Abbott Laboratories, Abbott Park,
Illinois, USA). HBV DNA levels were quantified by com-
mercial hybridization assay.
Peripheral blood mononuclear cells (PBMCs)
PBMCs were isolated from 50 mL of fresh whole blood
in 6 × 8 mL cell preparation tubes prefilled with 1 mL
0.1 M sodium citrate and 3 g of polyester gel, 2.0 mL of
FICOLL™ Hypaque™ solution (BD Vacutainer® CPT™).
Pellet was resuspended in RPMI-1640 with 20 % (v/v)
FCS and 10 % (v/v) DMSO and frozen in liquid
nitrogen.
HLA loci genotyping
High-resolution HLA class I typing was performed using
Sequence Based Typing method with PCR sequencing
templates performed on both strands. Sequencing DNA
templates was produced by locus- and group-specific
amplifications that include exon 2 and 3, which con-
tain the antigen recognition sites. Class I sequencing
primers where the common sequences for all loci in
the intron/exon boundary regions and a total of 40
locus and group-specific primers were used to amplify
the target sequences (HistoGenetics LLC, Ossining,
NY, USA).
Epitope selection
Published reports on acute and chronic HBV patient and
response to various HBV epitopes was studied and com-
pared to NetMHC version 3.2 predictions of 8-mer epi-
topes, using Artificial Neural Networks Approximation
(www.cbs.dtu.dk/services/) [6, 8, 9, 13–19]. Computer pre-
dictions were made on class I genotypes HLA-A11, HLA-
A24 and HLA-A2 since these genotypes covered the ma-
jority of our patientpopulation. The surface sequences
vary greatly among different HBV genotypes and subtypes
[20] and we observed single and double residue variations
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between the published sequences and sequences found in
the database of the computer algorithm. For this reason
we were not able to directly compare the findings of the
published reports with the computer predictions. The
computer predicted epitopes were designed by cross
matching the different HLA subtypes and HBV geno-
types of the study population. According to classifica-
tions made earlier [21], a dissociation constant KD < 50
nM predicted strong binding, 50–500 nM weak binding,
and KD > 500 nM predicted essentially no binding.
Analysis of protein parameters isoelectric point (pI)
[22], length, instability index [23] and aliphatic index
[24] were performed on each epitope (http://web.expa-
sy.org/protparam/).
Peptides mimetics of HBsAg-specific epitopes in ELISPOT
assays
Twenty HBsAg and HBcAg epitopes were purchased from
GL Biochem (Shanghai, China), with a purity > 95 % as
estimated from mass spectometry. We used HLA class I-
restricted T cell epitopes from human cytomegalovirus,
Epstein Barr virus and influenza virus (CEF) for positive
control (CTL-Europe GmbH, Germany).
Enzyme-linked immunospot (ELISPOT) assays were
performed using the 20 different peptides seeded in
separate wells. Briefly, 96-well plates (Multiscreen-IP;
Millipore S.A.S., Molsheim, France) were coated over-
night at 4 °C with 100 μL/well capture mouse anti-
human IFN-γ monoclonal antibody (AH diagnostics,
Aarhus, Denmark). Plates were washed twice with
ELISPOT coating buffer and blocked with CTL
serum-free media for 1–2 h at room temperature
(CTL-Europe GmbH, Germany). PBMCs (3 × 105/well)
were thawed and suspended in CTL serum-free media
then seeded in triplicate for each individual peptide.
Plates were incubated for 48 h at 37 °C and washed
with PBS and 0.05 % Tween-20. 100 μL/well biotinyl-
ated secondary mouse anti-human IFN-γ monoclonal
antibody was added according to manufacturer
recommendations. After 2 h incubation at room
temperature, plates were washed four times with PBS
and 0.05 % Tween-20, 100 μl of Avidin-HRP solution
was added to the wells, and the plates were incubated
for further 45 min at room temperature. Plates were
washed 3 times with PBS and 0.05 % Tween-20, and
2 times with PBS alone, and 100 μl of AEC substrate
solution (3-amino-9-ethyl carbazole) was added. After
10–15 min, the colorimetric reaction was stopped by
washing three times with distilled water. Plates were
air dried, and spots were counted and analyzed using
an automated ELISPOT reader (CTL-Immunospot S6
Analyzer, CTL GmbH, Germany). The T cell response
was assessed as spot forming cells (SFC) and mean
spot size (MSS). To exclude subjective assessment,
whether the background were related to the actually
response, we decided to use the stimulation index
(SI) for analysis, calculated by dividing the value of
the stimulated sample with the value of the unstimu-
lated control. Four uninfected individuals (with clean
HBV serology) were included to exclude unspecific
findings (data not shown). All patients responded vig-
orously to the positive CEF control.
Statistics
Statistical analysis was performed using GraphPad Prism
6 (©2014 GraphPad Software, Inc) and STATA/IC 13.1
(©2014 StataCorp, LP). Non-parametric measures were
analysed by Spearman’s correlation, Mann–Whitney U
test, Kruskal-Wallis test with Dunn’s correction for mul-
tiple comparison while parametric data were assessed by
Student’s T-test and one-way analysis of variance
(ANOVA).
Results
HLA genotypes and epitopes
Ten experimentally confirmed (EC) HBsAg and HBcAg
epitopes were chosen from the literature, and 10 8-mer
HBsAg and HBcAg epitopes were chosen based on the
computer predictions (CP) of HLA class I binding to the
epitopes (Tables 1 and 2). Among CHB patients, 12/30
(40 %) were HLA-A*02:01, 1/30 (3 %) HLA-A*02:03,
1/30 (3 %) HLA-A*02:06 and 1/30 (3 %) HLA-
A*02:17. Among RHB patients, 6/10 (60 %) were
HLA-A*02:01. We included one surface epitope tested
among patients with HLA-A*11 genotype and one
tested among HLA-A*24 genotype patients. Among
the patients, 5/30 (17 %) CHB patients and 2/10
(20 %) RHB patients had HLA-A*11 genotype, and 6/30
(20 %) CHB patients had HLA-A*24 genotype. No RHB
patients were HLA-A*24 genotype. Characteristics of
patients are shown in Table 3.
IFN-γ ELISPOT
Age-related data of the CHB and RHB patients were
tested for normality and equal SD and analysed by stu-
dents t-test. No significant difference was found between
the two groups (difference in year: −3.16 (CI: −14.1–7.8),
p = 0.72). To test whether the response to HBV epitopes
of the CHB patients depended on age, ethnicity and gen-
der, Kruskal Wallis oneway analysis of variance were per-
formed on each separate response parameter, SFC and
MSS. No significant difference of response was found
among the four ethnic groups Black African (n = 2), Arab
(n = 1), Asian (n = 12) and White European (n = 15),
p = 0.68 for MSS, p = 0.12 for SFC. Furthermore no
significant difference were found among males and
females, p = 0.55 for MSS, p = 0.13 for SFC. We have pre-
viously reported that age is an important determinant in
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humoral and T cell responses to immunization with hepa-
titis B surface antigen [25] so to test whether age were re-
lated to the response to HBV epitopes, we divided
patients in three groups: 23–30 years (n = 6), 31–49 years
(n = 13) and 50–73 (n = 11). No significant difference of
response were found between the groups, p = 0.15 for
MSS, p = 0.45 for SFC. Due to the limited number of pa-
tients in the RHB group, the statistical power was not
strong enough to make subanalysis.
The numbers of HBV-specific T cells producing
IFN-γ after stimulation with HBV epitopes were
similar in CHB and RHB patients. Furthermore, the
chronic patients surprisingly had a significantly higher
MSS SI (Fig. 1). Comparison of the area under the
curve (AUC) based on the response profiles of SFC
and SFC x MSS, found that difference in response
profiles did reach statistical significance when com-
paring SFC x MSS area (p < 0.0001). When stratifying
the analysis for patients with HLA-A2 and non HLA-
A2 genotype, the group of non HLA-A2 were found
with significantly higher SI of SFC and MSS, the results
being even more distinct when only the CHB patients
Table 1 HLA class I restricted epitopes (I)
Number Residues Sequence HLA Reference
HBsEC-1 20–28 FLLTRILTI A*02:01, 02:05, 02:06 [13]
HBsEC-2 88–96 LLCLIFLLV A2 [9, 14]
HBsEC-3 95–104 LVLLDYQGML A2 [8]
HBsEC-4 172–180 WLSLLVPFV A*02:01, 02:02,02:03,02:05, 02:06 [6, 8, 9, 14, 15]
HBsEC-5 207–216 SIVSPFIPLL A2 [14]
HBsCP-6b 169–176 FLGPLLVL A2a
180–187
179–188
HBsCP-7b 72–79 LLGWSPQA A2a
61–68
71–78
HBsCP-8b 259–266 LLLCLIFL A2a
248–255
258–265
HBsCP-9b 333–370 FLWEWASA A2a
332–339
322–329
HBsCP-10b 129–136 PAGGSSSG A2a
140–147
139–146
HBcEC-11 18–27 FLPSDFFPSV A*02:01, 02:05, 02:06 [6, 8, 9, 14–17]
HBcEC-12 88–96 YVNVNMGLK A11 [18]
HBcEC-13 107–115 CLTFGRETV A2 [8]
HBcEC-14 117–125 EYLVSFGVW A24 [19]
HBcEC-15 139–148 ILSTLPETTV A2 [8]
HBcCP-16 141–148 TLPETTVV A2
HBcCP-17 160–168 PSPRRRRS A2
HBcCP-18 64–71 LMTLATWV A2
HBcCP-19 29–36 LLDTASAL A2
HBcCP-20 107–114 LTFGRETV A2
Name and amino acid position of the 20 epitopes. HLA genotype indicates which genotypes were tested in previous studies (HBsEC1-5 and HBcEC11-15), or which
genotypes we stratified for in the in silico analysis (HBsCP6-10 and HBcCP16-20)
HBsEC HBsAg experimentally confirmed, HBsCP HBsAg computer predicted, HBcEC HBcAg experimentally confirmed, HBcCP HBcAg computer predicted
aall subtypes
bdifferences of sequence position among HBV genotypes was observed for in silico prediction of HBsAg
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were included in the analysis, MSS: p < 0.0001, SFC:
p = 0.0099 (Fig. 2). AUC analysis confirmed the response
profile to be significantly different. Analysing the SI strati-
fying for various HLA genotypes, only patients with HLA-
A11 had significantly stronger SI of MSS (Fig. 3). AUC
analysis of CHB patients with HLA-A11 genotype com-
pared to RHB patients with HLA-11 genotype and CHB
patients with HLA-A2 genotype respectively, revealed
statistical significance in SFC x MSS response profile
(p < 0.0001). Additionally, HBeAg positive patients, all
with higher viral load, had a significantly lower SI of
MSS, and none of the HBeAg positive patients had
HLA-A11 genotype (Fig. 4).
Correlations of SFC and MSS
To determine whether number of spots correlated with
spot size, e.g. is the frequency of HBV specific T cells pro-
portional with the functionality, we correlated SFC and
MSS in all different groups. Using spearman’s correlation,
no significance was found, but a trend towards correlation
was found in all groups (data shown for chronic patients
with/without HLA-A2 genotype in Fig. 2c).
Computer prediction of immunoreactive epitopes
We compared the epitopes from the literature (ex-
perimentally confirmed, EC, epitopes 1–5 and 11–15)
with epitopes computer predicted (CP, epitopes 6–10
and 16–20) to assess the ability of the computer algo-
rithm to determine HBV epitopes. We compared the
SI in 4 groups: Chronic and resolved HBV, HLA-A2
genotype and non HLA-A2 genotype, HLA-A11,
HLA-A2 and other HLA genotypes, HBeAg positive
and HBeAg negative patients. We analysed HBsAg
and HBcAg epitopes together and separately, respect-
ively, and found no significant difference in response
towards epitopes experimentally confirmed compared
with epitopes computer predicted.
Analysis of protein parameters included isoelectric
point, length, instability index and aliphatic index and
were performed for each epitope. We analysed the pa-
rameters in 4 groups: HBsAg epitope 1–5 EC, HBsAg
epitope 6–10 CP, HBcAg epitope 11–15 EC, and HBcAg
epitope 16–20 CP. No correlation between the different
parameters and SI were found (data not shown). No sig-
nificant difference where found between the groups
(data not shown).
Epitope assessment
We assessed the individual epitopes capability of
eliciting specific T cell response, by the amount of
IFN-γ produced. MSS SI varied widely within the
groups. We found that 6 epitopes generally elicited a
higher SI in all groups (Table 4). Three epitopes were
already experimentally confirmed (EC-1, −4 and −11),
and three epitopes where computer predicted (CP-7, −9
and −17).
Discussion
Based on findings in several past studies, we hypothe-
sized that a stronger IFN-γ response would be produced
in PBMC from resolved HBV patients compared to
PBMC from chronic HBV patients when stimulating
with 20 individual HBV epitopes and quantifying IFN-γ
response by of number of spot forming units and the
amount of IFN-γ produced. Surprisingly, T cells from
CHB patients recognized a similar number of CTL epi-
topes compared to T cells from RHB patients. We ob-
served a relatively unimpaired cytokine response with
higher levels of IFN-γ in CHB patients, in patients with-
out HLA-A2 genotype, patients with HLA-A11 geno-
type, and we found lower levels of IFN-γ production in
patients with high viral load (HBeAg positive). These re-
sults suggest that the impaired immune response in
CHB is not solely due to impaired production of IFN-γ.
Indeed, IFN-γ remains as an important component of
the overall immune response required combating infec-
tion with HBV. Note that in our study the average
Table 2 HLA class I restricted epitopes (II)
Number Response
AHB
Response CHB KD Reference
HBsEC-1 14/23 N/A N/A [13]
HBsEC-2 6/13 1/15 N/A [9, 14]
HBsEC-3 N/A 16/17 N/A [8]
HBsEC-4 42/56 5/33 N/A [6, 8, 9, 14, 15]






HBcEC-11 41/59 9/30 50–10,000 nM [6, 8, 9, 14–17]
HBcEC-12 N/A 1/1 N/A [18]
HBcEC-13 N/A 2/5 >50 nM [8]
HBcEC-14 7/12 0/11 >500 nM [19]






All KD values are in silico predictions by NetMHC version 3.2 8mer predictions.
HBsEC: HBsAg experimentally confirmed; HBsCP: HBsAg computer predicted;
HBcEC: HBcAg experimentally confirmed; HBcCP: HBcAg computer predicted.
N/A: Not available, AHB and CHB referres to number of responders in previous
studies of acute hepatitis B (AHB) and chronic hepatitis B patients (CHB)
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Table 3 Patient characteristics
ID Age Sex Ethnicity HLA class I HBeAg
C1 57 F Black African A2A24 B44B58 C3C16 Neg
C2 46 F Asian A24A31 B35B51 C1C14 Neg
C3 43 M Arab A2A3 B44B47 C6C16 Neg
C4 35 M Asian A11A33 B44B55 C3C7 Neg
C5 52 M Asian A2A33B40B51 C14C15 Pos
C6 33 M White European A2 B14B18 C7C8 Neg
C7 49 F Asian A1A11 B35B52 C4C7 Neg
C8 39 F White European A3A74B15B35 C4 Neg
C9 29 F White European A1A32 B40B44 C3C16 Neg
C10 65 M White European A2A29 B7B44 C7C16 Pos
C11 30 F White European A2 B38B51 C12C15 Neg
C12 26 F White European A2A24 B18B38 C7C12 Neg
C13 43 F Asian A2A26 B56B59 C1C7 Neg
C14 46 M White European A1A2 B37B51 C6C15 Neg
C15 73 M White European A2A3 B7 C7 Neg
C16 53 M Asian A11A24 B13B18 C3C7 Neg
C17 29 F White European A2 B13 C6 Neg
C18 61 F Asian A11A33 B13B58 C3 Neg
C19 40 F Asian A11A33 B44B59 C1C14 Neg
C20 51 F Black African A29A30 B18B45 C6C7 Pos
C21 34 F Asian A24A26 B13B40 C3C6 Pos
C22 30 M White European A2A26 B38B51 C12C15 Neg
C23 62 F White European A2A68 B15B44 C3C7 Neg
C24 51 M White European A2A3 B7B18 C7 Neg
C25 61 M White European A2A26 B7B51 C1C12 Neg
C26 34 F Asian A24A26 B13B40 C3C6 Pos
C27 61 F White European N/A Neg
C28 49 M Asian N/A Neg
C29 37 M Asian N/A Pos
C30 23 M White European N/A Neg
R31 40 F White European A2 B15B44 C1C5
R32 30 F White European A2A68 B35B44 C4C5
R33 N/A N/A White European A2A26 B38B40 C12C15
R34 48 M White European A23A26 B35B44 C4
R35 65 F White European A1A2 B7B8 C7
R36 43 F White European A1A11 B8B15 C7
R37 38 M White European A2A11 B15B55 C3
R38 69 F White European A2 B7B8 C7
R39 73 F White European N/A
R40 25 F White European N/A
Normal ALT levels were found in all patients except patient C18 and C19 where ALT levels were elevated to 59 and 66 IU/mL (normal range for females is
10–45 IU/mL). No patients were double positive or double negative for HBeAg/anti-HBeAg. Median HBV DNA in the HBeAg positive patients were 81,000 IU/mL
(2 – 400.000 IU/mL) and 0.019 IU (0 – 5500 IU/mL) in the HBV negative patients, no statistics were made on HBV genotype since quantification was not possible
in 12 of the 30 patients. N/A: not available; F: female; M: male; Pos: positive; Neg: negative
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stimulation index did not exceed 6, which still indicates
a low IFN-γ production. Since the majority of epitopes
were designed to give a strong response in patients with
HLA-A2 genotype, with little difference among HLA-
A*02 subtypes, and since we found a stronger response
in patients with HLA-A11, this may suggest HLA-A11 is
protective. No patients were both HLA-A11 and HBeAg
positive and this supports HBeAg as a virulence factor
and that control of HBV is more complex than T cell
capability of IFN-γ production alone [26]. Other studies
Fig. 2 ELISPOT results of chronic HLA-A2 patients. a Stimulation
index (SI) for CHB patients divided in two groups: Patients with the
HLA-A2 genotype and patients without HLA-A2 genotype. Each
datapoint represents the mean response to each individual epitope.
The patients without HLA-A2 genotype had a significantly higher
amount of IFN-γ production. If we included RHB patients in the
analysis, the results were still significant. Unpaired two-tailed t-test
with equal SD, N = 15 in each group, **** indicates p < 0.0001,
** indicates p = 0.0099. b AUC showed that difference in response
profiles did reach statistical significance when comparing SFC x MSS
area, Kruskal-Wallis (Dunn’s) multiple comparisons test, *** indicates
p = 0.0009. c Spot number correlated with spot size. No significant
correlation was found
Fig. 1 ELISPOT results of chronic and resolved HBV patients.
a Stimulation index (SI) for CHB and RHB patients. Each datapoint
represents the mean response to each individual epitope. No
difference where found in the frequency of spot forming cells. The
CHB patients had a significantly higher amount of IFN-γ production.
Unpaired two-tailed t-test with equal SD, N = 10 RHB patients,
N = 30 CHB patients, **** indicates p < 0.0001. b AUC showed that
difference in response profiles did reach statistical significance
when comparing SFC x MSS area, Dunn’s multiple comparisons test,
R; resolved, C; chronic, **** Indicates p < 0.0001. c Picture from the
data-analysis of a RHB and CHB patient. Large circle indicates the
counted area. Small circles indicate the counted spots
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report that the amount of cytokine secreted by individ-
ual antigen specific T cells rather than differences in fre-
quencies was the factor responsible for immune
deficiencies in patients with HIV infection [27]. No stud-
ies have reported correlation between MSS and SFC in
HBV infection. Most studies on HBV focus on SFC as
the primary response parameter [28–30]. One tubercu-
losis vaccination study of non-human primates, found
that spot size in combination with spot number, was key
in determining a protective immune response [31]. We
found no correlation between SFC and MSS respectively,
but where able to describe similar results regarding SFC
combined with MSS.
The three experimentally confirmed (EC) epitopes
with highest SI (epitope 11 being HBcAg 18–27 which
previously has been described as being highly im-
munogenic [10, 32, 33]) correlated with observations
from previous studies. The three new computer pre-
dicted (CP) epitopes HBsCP-7, HBsCP-9 with predicted
KD < 50 and HBcCP-17 with predicted KD > 500, may be
worth examining in future studies. Surprisingly we saw a
high SI when stimulation with HBsCP-17 despite the high
KD value, and this suggest that the CTL-inducing effect of
an antigenic peptide not always correlate with the com-
puter estimated KD value [8, 9]. However, our results indi-
cate that software both predict new epitopes as well as
confirm previously described epitopes.
The liver cellular environment offers opportunities for
immune evasion, which may partly explain why the im-
mune response towards HBV frequently fails in the liver.
Does this indicate HBV as a well-adapted pathogen - or
is it the Th2 biased environment in the liver that permits
the path to chronicity? The liver is an important site for
T cell activation, however, the environment is biased to-
wards induction of tolerance. This is partially due to the
ongoing synthesis of IL-10 by cells constitutively ex-
posed to traces of endotoxin and other microbial prod-
ucts [34]. In addition, the structure of the liver enables
open access of naïve T cells to diverse subsets of antigen
presenting cells (APCs). As a result, formation of mem-
ory T cell is lacking in this tissue since CD8+ T cell
Fig. 3 ELISPOT results of HLA-A11 and non-HLA-A11 patients.
a Stimulation index (SI) for patients divided in 5 groups. Each
datapoint represents the mean response to each individual epitope.
CHB patients with HLA-A11 had significantly higher SI of MSS
compared to all other group. No significance were found when
analysis spot forming cells; R: resolved; C: chronic. Unpaired one-way
ANOVA, Kruskal-Wallis (Dunn’s) multiple comparison test, Non HLA-A11
(R) (N = 8), HLA-A11 (R) (N = 2), HLA-A2 (C) (N = 15), Other HLA (C)
(N = 10), **** indicates p < 0.0001, top line: 95 % CI of difference
(−2.8;-1.9), middle line: 95 % CI (−2.7;-1.8), bottom line: 95 % CI
(−2.4;-1.6), **: 95 % CI (1.1;1.9). b AUC showed that difference in
response profiles did reach statistical significance when comparing
SFC x MSS area, Kruskal-Wallis (Dunn’s) multiple comparisons test,
**** indicates p < 0.0001
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priming occurs without concomitant CD4+ T cell activa-
tion [35]. Furthermore, in the liver most APCs express
PD-L1 providing the capacity to inactivate T cells. These
mechanisms may be a key factor in the immunotoler-
ance in chronic HBV in agreement with ours and the re-
sults of the investigations by others, this suggest that
IFN-γ production is not the single major component in
HBV clearance. Previous studies found a long lasting T
cell response only after an acute infection [5, 6]. Our
findings suggest, however, that these observations should
be interpreted with caution. Memory CD8+ T cells can
be divided into two subsets, namely central (TCM) and
effector (TEM), which predominantly are found in the
lymph node and in circulation, respectively. Neverthe-
less, their individual ability to confer protective immun-
ity is not all clarified. One study found that TCM were
more efficient in mediating protective immunity result-
ing in antigen clearance, and that TEM converts to TCM
in a lineage differentiation pathway. Furthermore, these
results demonstrate that long-term persistence of mem-
ory T cells is primarily in the form of TCM and that
400 days post infection, 95 % of all T cells were CCR7hi
[36]. This may explain our low response among the re-
solved HBV patients, since the blood was taken from the
periphery, and all donors had been infected more than
2 years ago. Recently, Loggi et al. found the total
breadth and magnitude of HBV specific T cell re-
sponses in IFN-γ ELISPOT did not differ significantly
between groups of CHB and RHB patients [29] in
accordance with our results.
We found evidence that HBeAg status and HLA-type
affected the amount of IFN-γ production. IL-7 signaling
is essential to CD8+T cell proliferation and function [37]
and persistent viral antigen load suppresses CD127 ex-
pression, i.e., the α-chain on the IL-7 receptor on primed
T cells. Studies have found that CD127 negatively corre-
lates with serum HBV DNA and HBeAg levels in
chronic HBV [38]. In addition to the impaired CD127
expression, exhausted HBV-specific T cells in the liver
display increased PD-1 expression [39]. In several studies
the PD-1/PD-L1 pathway has been shown to contribute
Table 4 Epitope assessment
HBsEC-1 HBsEC-4 HBsCP-7 HBsCP-9 HBcEC-11 HBcCP-17
Chronic 2,2 2,4 2,2 2,2 2,8 2
Resolved 1,1 1,2 1,8 1,6 1 0,9
HLA-A2 1,5 1,4 1,6 1,7 1,3 1,3
Non A2 2,9 3,1 2,6 2,7 3,1 2,6
Chronic HLA-A11 4,5 5 4,3 4,4 4 4
HBeAg positive 2 1,6 1,3 1,2 1,9 3
HBeAg negative 2,2 2,6 2,4 2,5 3 2,1
The assessment is based on stimulation index of mean spot size. HBsEC: HBsAg experimentally confirmed; HBsCP: HBsAg computer predicted; HBcEC: HBcAg
experimentally confirmed; HBcCP: HBcAg computer predicted
Fig. 4 ELISPOT results of HBeAg positive and negative patients.
a Stimulation index (SI) for CHB patients divided in HBeAg positive
and HBeAg negative. Each datapoint represents the mean response
to each individual epitope. CHB patients with HBeAg negative had
significantly higher SI of MSS compared to HBeAg positive patients,
and the contrary were found in number of spot forming cells,
unpaired two-tailed t test with equal SD, HBeAg negative (N = 24),
HBeAg positive (N = 6), **** indicates p < 0.0001, *** indicates
p = 0.0009. b AUC did not reach statistical significant difference in
Kruskal-Wallis (Dunn’s) multiple comparisons test
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to the suppression of HBV-specific T cell function and
IFN-γ secretion is rapidly suppressed despite a contin-
ued presence of antigens. This loss of function coincides
with the up-regulation of PD-1 [40]. We now report that
a higher viral load in HBeAg positive patients influenced
the number of HBV-specific T cells. Despite the higher
number of SFC, however, the amount of IFN-γ produced
was impaired compared to patients negative for HBeAg.
This suggests that the IFN-γ producing subset of T cells
may possibly be inactivated or exhausted by PD-1 link-
age and CD127 down regulation while T cell ability to
register and bind to the antigen is partly maintained.
To date, no HLA class I allele has been confirmed to
be a protective or risk factor of CHB. However, many
proposals have been made [41, 42] and, indeed, our find-
ings are in support of some of these previous studies.
The IFN-γ production was significantly higher in CHB
patients with HLA-A11 genotype compared to the other
groups, and with the highest SI levels observed among
all groups tested (Fig. 3a). It has been reported previ-
ously that HLA-A11 may contribute in the development
of natural immunity against HBV [43] and HLA-A11
were among the most common genotypes of responders
to an HBsAg vaccine [44].
Conclusion
In conclusion, our study suggests IFN-γ mean spot size as
an important supplementary marker for T cell specificity,
providing a measurement of the amount of IFN-γ when T
cells fails to elicit response as calculated from number of
specific T cells. This readout was found to enhance the dis-
criminatory power of the ELISPOT assay and provide more
information on the IFN-γ response profile of CHB and
RHB patients. Furthermore, we showed that the computer
program NetMHC version 3.2 8mer predictions, using
Artificial Neural Networks Approximation could be a valu-
able tool in future studies regarding HLA genotypes and
HBV epitopes. Hence, we found 3 immunogenic epitopes
not previous described. Finally, our study highlights the role
of the HLA-A11 allele in HBV infections with potential im-
plication for both acquiring the disease and as inducing
protective immunity by vaccination.
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